跳至主要内容
临床试验/NCT01865669
NCT01865669已完成不适用

In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity

Samuel Lunenfeld Research Institute, Mount Sinai Hospital1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2013年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
44
试验地点
1
主要终点
Motility index

研究概览

简要总结

Women with advanced maternal age and morbid obesity, have a higher incidence of labor induction/ augmentation and cesarean section (CS), and are at a greater risk for postpartum hemorrhage (PPH). Oxytocin is the first line drug in the treatment of PPH, however, oxytocin receptor (OTR) desensitization has been recognized in the context of prolonged labors secondary to either endogenous or exogenous oxytocin exposure. It is unknown if oxytocin desensitization specifically affects contractility in women with advanced maternal age and morbid obesity when compared to younger or normal weight populations. Further it is not known if the higher incidence of PPH seen in these women is due to poor uterine contractility and/or poor response to oxytocin.

The investigators hypothesize that women with advanced maternal age and morbid obesity will exhibit poor myometrial contractility as compared to women that are younger and of normal body habitus, in both oxytocin pre-treated and untreated myometrium.

详细描述

In view of the growing concern over the rising incidence of later maternal age and morbid obesity in the obstetric population, scientific evidence on pregnancy outcomes in these patients is timely and important. The investigators' previously validated in-vitro model provides a solid foundation for the study of myometrial contractility under controlled conditions, without any confounders that could be encountered in clinical settings. It is also likely to provide in-depth understanding of the parameters that the investigators feel are responsible for higher incidence of PPH in these patients. The investigators' study will form a basis for future modifications in oxytocin augmentation regimens and pharmacotherapy for control of PPH in these patient populations.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • patients who give written informed consent
  • patients requiring elective primary or 1st repeat Cesarean section
  • patients with gestational age 37-41 weeks
  • non-labouring patients, not exposed to exogenous oxytocin
  • Cesarean section under spinal anesthetic
  • patients <30 years of age with a normal pre-pregnancy BMI (20 and 24.9 kg/m2)
  • patients ≥40 years of age with a normal pre-pregnancy BMI
  • patients with a BMI≥40 kg/m2 and age <30 years

排除标准

  • patients who refuse to give written informed consent
  • patients who require general anesthesia
  • patients who have had more than one previous uterine surgery/CS
  • patients with placental abnormalities (abruption, accreta, percreta)
  • patients with bleeding disorders
  • presence of any other risk factors for PPH

研究组 & 干预措施

Oxytocin

Experimental

Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.

干预措施: Oxytocin (Drug)

结局指标

主要结局

Motility index

时间窗: 6-8 hours

次要结局

  • Frequency of contraction(6-8 hours)
  • Amplitude of contraction(6-8 hours)
  • Integrated area under response curve (AUC)(6-8 hours)

研究者

发起方
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验